Rinaldo Caro Sanchez

Experienced internal medicine physician and principal investigator with a strong track record of leading research teams and maintaining high ethical standards. Demonstrated success in delivering impactful research results. Built a comprehensive and diverse database of clinical trial participants, supported by a vast professional network.

• Board Certified, Internal Medicine
• Medical License, Florida, ME 106399

• Life's and Benefits of cannabidiol and tetrahYdrocannabidol (LIBBY) by National Institute on Aging (NIA)
• A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic HCV
• A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SYVN-502) for the Treatment of Agitation in Participants with Dementia of the Alzheimer's Type
• Phase III Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• A multicenter randomized, double-blind, placebo-controlled 12 week study to evaluate the safety and efficacy of oral Difelikefalin in advanced chronic kidney disease subjects with moderate to severe pruritus with an up to 52 week long term extension
• A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial with a quetiapine arm to evaluate the efficacy, tolerability, and safety of oral Bl 1358894 in patients with Major Depressive Disorder with inadequate response to antidepressants
• A Randomized, double-blind (patient, investigator), placebo-controlled, Parallel-group, single-dosing study on safety, tolerability, pharmacokinetic and preliminary efficacy of Bl 1569912 as adjunctive therapy in patients with major depressive disorder
• Phase 4, randomized, double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks IP bid for smoking cessation in subjects with and without a history of psychiatric disorders
• A randomized, double-blind, placebo-controlled, efficacy, safety, and tolerability study of IP in the treatment of elderly subjects with psychosis and behavioral disturbances associated with dementia of the Alzheimer's type
• A phase Ill randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Ip once daily over 26 week treatment period in patients with schizophrenia (connex2)
• Study in stabilized schizophrenic patients to evaluate the pharmacokinetics of IP when it is administered from a polyurethane implant
• Ahead 3-45 study: a placebo-controlled, double-blind, parallel-treatment arm, 216 week study to evaluate efficacy and safety of treatment with IP in subjects with preclinical Alzheimer's disease and elevated amyloid (a45 trial) and in subjects with early preclinical Alzheimer's disease and intermediate amyloid (a3 trial)
• A phase III, open-label, parallel-group, 2-arm study to investigate amyloid plaque clearance with IP compared with IP in participants with early symptomatic Alzheimer's disease
• Phase Ill, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of IP in patients with early (prodromal to mild) Alzheimer's disease
• A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer's Type
• An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of Alzheimer's Type
• Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 when administered to participants with Alzheimer's disease and vascular pathology
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
• Assessment of safety and efficacy measured by amyloid reduction of Remternetug in early symptomatic Alzheimer's disease. Jl G-MC-LAKC
• Randomized, Delayed Start, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study of Piromelatine 20 Mg in Participants with Mild Dementia due to Alzheimer's Disease
• Phase Il trial to evaluate efficacy, safety and tolerability of multiple subcutaneous doses of IP in patients with non alcoholic steatohepatitis (NASH) and fibrosis
• A 26-week, phase 2b, 2-part, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of ip administration in adults with obesity
• A phase 2a, 2-part, randomized, double-blind, double-dummy placebo-controlled, parallel-group (sponsor open) study to assess pharmacodynamics and safety of IP coadministered with IP in adult participants with presumed nonalcoholic steatohepatitis (NASH)
• A randomized, double-blind, placebo-controlled, multicentre, phase 3 study evaluating long-term efficacy and safety of IP in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (f2)/fibrosis3 (f3) stage of liver fibrosis
• A phase 2, randomized, double-blind, double-dummy, placebo-controlled, dose-ranging, dosefinding, parallel group study to assess efficacy and safety of ip alone and when administered with IP in adult participants with biopsy confirmed nonalcoholic steatohepatitis and fibrosis stage 2 or 3
• A phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacodynamic effects of IP in obese subjects with nonalcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH)
• A Phase ll, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis
• Efficacy and safety investigation of NNCOI 94-0499 co-administered with semaglutide in subjects with nonalcoholic steatohepatitis: a dose-ranging, placebo-controlled trial
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NGIOI Administered Orally to Patients with Gastroparesis
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in Combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH)
• A randomized, double-blind trial to test higher- versus lower-doses of IP on inflammatory markers and platelet biomarkers and nitric oxide formation & endothelial function in secondary prevention (pts w/chronic stable coronary disease)
• Zilebesiran as Add-on Therapy in Patients with Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
• Phase Ill, randomized, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity
• Multi-center, randomized, double-blind, placebo-controlled study of IP in patients with mild moderate Covid- 19
• A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody IP for the early treatment of coronavirus disease 2019 (covid-1 9) in nonhospitalized patients
• A phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody IP given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (covid-19) in high-risk non-hospitalized patients
• A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBl-0451 Compared with Placebo in Non hospitalized Symptomatic Adults with COVID-19

• Advanced Principal Investigator Physician Certification (APICPC)
• CCRPS
• ACLS/BCLS certified
• Member of Society of Hospitalist Medicine
• Good clinical practice
• Human subject training
• Rating Scales related to Dementia, Agitation, Depression, Dermatology, Psychiatry